Rezolute has commenced a pivotal Phase 3 clinical trial for its investigative drug, RZ358, aimed at treating patients with Congenital Hyperinsulinism.

Mission Therapeutics reveals that the FDA has given the green light to start a Phase II study for their prime candidate, MTX652, targeting Acute Kidney Injury.

Halia Therapeutics initiated treatment with HT-6184, a novel NLRP3 inhibitor, in an initial participant for its early-stage Phase 2a study aimed at addressing lower-risk types of myelodysplastic conditions.

Agomab Initiates First-Stage Research Trial on AGMB-447 with Healthy Participants and Individuals Diagnosed with Idiopathic Pulmonary Fibrosis.

FDA has accorded an expedited evaluation to the drug Tarlatamab, developed by Amgen, which is aimed at treating advanced-stage small cell lung cancer.

Maze Therapeutics has commenced the administration phase of its Phase 1 clinical evaluation of MZE829 to test subjects in good health.

1ST Biotherapeutics, Inc. breaks new ground as it initiates the first human trial stage I/II by administering FB849, to individuals with progressive solid cancers

C4 Therapeutics, Inc., a company developing targeted protein degradation drugs, has announced early results from its Phase 1/2 trial's initial dose-escalation stage. The trial evaluates CFT7455, a unique MonoDAC™ agent targeting IKZF1/3 proteins, for treating multiple myeloma and non-Hodgkin lymphomas.

Shattuck Labs Reveals Promising Early Results from Continual Phase 1 A/B Clinical Study of SL-172154 Combined with Azacitidine in Newly Diagnosed Advanced Myelodysplastic Conditions (HR-MDS) and TP53 Mutation-Positive Acute Myeloid Leukemia Patients.

Plexium has begun dosing in a Phase 1 trial for its oral drug PLX-4545, a molecular glue degrader targeting the previously "undruggable" transcription factor IKZF2, also known as Helios.

The European Commission has sanctioned Blueprint Medicines' drug AYVAKYT® (avapritinib) as the exclusive therapeutic option for indolent systemic mastocytosis.

Clover Biopharmaceuticals, Ltd. has announced the enrollment of the first group of participants for its Phase I clinical trial evaluating the SCB-1019 vaccine against Respiratory Syncytial Virus (RSV).